TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage biopharmaceutical company developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers, announced that its board of directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its oncology portfolio, including lead product candidate TTX-MC138. The review will consider potential licensing or sales of individual assets, development and commercialization partnerships, portfolio transactions, business combinations and other strategic alternatives.
The company has engaged Tungsten Advisors as its exclusive strategic financial adviser for the process. TTX-MC138, an investigational RNA-based therapeutic targeting microRNA-10b, has advanced into Phase 2a clinical development following a Phase 1a study that provided initial safety data and reports of stable disease. The ongoing trial is evaluating the treatment in patients with circulating tumor DNA-positive colorectal cancer following curative-intent therapy, in collaboration with Quantum Leap Healthcare Collaborative.
TransCode also recently announced a collaboration with Natera Inc. to use its Signatera test to identify eligible patients and support trial enrollment. Chairman and CEO Philippe P. Calais said the strategic review is intended to identify opportunities to advance the company’s oncology programs while seeking to maximize stockholder value. TransCode cautioned that the process may not result in a transaction or other strategic outcome.
The strategic review is significant for investors and the oncology community because it could lead to a range of outcomes, from asset sales to a full business combination, potentially accelerating the development of TTX-MC138 and other pipeline candidates. For patients with advanced cancers, particularly metastatic tumors that overexpress microRNA-10b, this could mean faster access to novel therapies if a partner with greater resources is brought in. The review also signals that TransCode is exploring all avenues to unlock value from its portfolio, which includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
To view the full press release, visit https://ibn.fm/AGxas. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ. This announcement is distributed by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
